白介素2+干扰素+恩替卡韦+乙肝疫苗多中心4期临床试验

MP4

https://clinicaltrials.gov/ct2/show/NCT02360592
同济医院宁琴教授主持
白介素2+普通干扰素a-2b+恩替卡韦+60ug乙肝疫苗

Locations
China, Anhui
Anhui Provincial Hospital       
Hefei, Anhui, China
China, Beijing
BeiJing YouAn Hospital, Capital Medical University       
Beijing, Beijing, China
First Hospital, Beijing University       
Beijing, Beijing, China
People'S Hospital Under Beijing University       
Beijing, Beijing, China
China, Fujian
The First Affiliated Hospital of Fujian Medical University       
Fuzhou, Fujian, China
China, Guangdong
Department of infectious disease, Nanfang Hospital of Southern Medical University       
Guangzhou, Guangdong, China
China, Hubei
Tongji Hospital       
Wuhan, Hubei, China, 430030
China, Hunan
Departmen of infectious disease, Xiangya Hospital, Central-south Universit       
Changsha, Hunan, China
China, Liaoning
ShengJing Hospital of China Medical University       
Shenyang, Liaoning, China
China, Shanghai
Shanghai Ruijin Hospital, Jiao Tong University School of Medicine       
Shanghai, Shanghai, China
China, Zhejiang
The First Affiliated Hospital of College of Medicine, Zhejiang University       
Hangzhou, Zhejiang, China
The first affiliated hospital of Wenzhou medical universtiy       
Wenzhou, Zhejiang, China

齐欢畅2

关注联合用药的尝试。
坚信。。。。。。

MP4

宁琴教授之前有做拉米加阿德天仙配的联合用药临床研究

ihc08

自己在恩替十派尝试3月了抗原上升又下降中....

MP4

ihc08 发表于 2016-12-13 22:16
自己在恩替十派尝试3月了抗原上升又下降中....

多少

MP4

http://www.apasl2017.org/images/ ... L2017_Abstracts.zip

S82页 OP111

MP4

在22日下午进行的专题报告中，宁琴教授还报告了传染病重大专项支持的两项全国多中心随机对照的临床研究（Endeavor和 Anchor）。研究针对广大NA经治患者，对其采用包括干扰素、治疗性乙肝疫苗和其他免疫因子，如IL-2、GMCSF等免疫调节剂的多靶点联合治疗，有望进一步提高CHB的临床治愈率。Endeavor中期数据表明，多靶点联合免疫治疗显著提高了HBsAg的下降水平，并提高了HBsAg的阴转率。宁琴教授表示，联合免疫治疗将会成为很重要的一个工作方向。
http://www.alabmed.com/content-134-2561-1.html